CNSP Stock — CNS Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$5.11

Market cap

$7.5M

Cash

$20.0M

Enterprise value

-$12.5M

Balance sheet

Cash	$20.0M
Debt	$0.0M
Net cash	$20.0M
Enterprise value	-$12.5M
Basic shares	1.5M shares
Fully diluted shares	2.2M shares
Fully diluted market cap	$11.2M
Cash per share	$13.32

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CNSP daily closes…

Loading price history…

Pipeline assets

Berubicin

Stage not disclosed · Active

Indications

Glioblastoma Multiforme, Adult (Phase 2)

Status note Legacy asset being out-licensed after Mar 2026 pivot away from glioblastoma focus; clinical trial enrollment and patient treatment complete, trial being closed out.

TPI-287

Stage not disclosed · Active

Target microtubules

Status note Legacy asset being out-licensed; IP under license agreement with Cortice; TPI-287 manufacturing and research costs incurred in 1H 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Berubicin
Lead indication	Glioblastoma Multiforme, Adult
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04762069	Phase 2	Active, not recruiting	Sponsor	CNS Pharmaceuticals, Inc.	—	Glioblastoma Multiforme, Adult	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for CNS Pharmaceuticals, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	135,830	+90,000	0.11%	2026-08-14
ADAR1 Capital Management	70,000	+70,000	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CNSP — CNS Pharmaceuticals Inc.